Skip to main content
. 2023;24(12):4269–4275. doi: 10.31557/APJCP.2023.24.12.4269

Table 2.

Knowledge Assessment of Women at All Sites

Parameter AIIMS ND
Site 1
N (%)
GKNM
Site 2
N (%)
AIIMS R
Site 3
N (%)
PGIMER
Site 4
N (%)
SJH
Site 5
N (%)
MGIMS
Site 6
N (%)
Total
N (%)
Heard of cervical cancer 124 (41.3) 189 (63.0) 282 (94.0) 69 (23.0) 7 (2.3) 152 (50.7) 823 (45.7)
Symptoms of cervical cancer
Postmenopausal Bleeding 08 (2.7) 40 (13.3) 0 (0.0) 11 (3.67) 0 (0.0) 28 (9.3) 87 (4.8)
Postcoital bleeding 05 (1.7) 05 (1.7) 33 (11.0) 02 (0.7) 01 (0.3) 57 (19.0) 103 (5.7)
Intermenstrual bleeding 20 (6.7) 24 (8.0) 45 (15.0) 04 (1.3) 00 (0.0) 11 (3.7) 104 (5.7)
Vaginal discharge 24 (8.0) 33 (11.0) 42 (14.0) 05 (1.7) 00 (0.0) 120 (40.0) 224 (12.4)
Hematuria 04 (1.3) 09 (3.0) 05 (1.7) 08 (2.7) 00 (0.0) 24 (8.0) 50 (2.8)
Weight loss 05 (1.7) 18 (6.0) 01 (0.3) 01 (0.3) 00 (0.0) 01 (0.3) 26 (1.4)
Risk Factors
Multiparity 04 (1.3) 10 (3.3) 00 (0.0) 15 (5.0) 01 (0.3) 50 (16.7) 80 (4.4)
Prolonged oral contraceptives 05 (1.7) 28 (9.3) 00 (0.0) 03 (1.0) 00 (0.0) 79 (26.3) 115 (6.4)
HPV infection 07 (2.3) 26 (8.7) 18 (6.0) 03 (1.0) 00 (0.0) 00 (0.0) 54 (3.0)
Early marriage 06 (2.0) 15 (5.0) 02 (0.7) 32 (10.7) 00 (0.0) 25 (8.3) 80 (4.4)
Smoking 03 (1.0) 11 (3.67) 30 (10.0) 03 (1.0) 00 (0.0) 22 (7.3) 69 (3.8)
Poor menstrual hygiene 07 (2.3) 17 (5.7) 31 (10.3) 05 (1.7) 00 (0.0) 58 (19.3) 118 (6.5)
Reduced immunity (HIV/Transplant patients) 02 (0.7) 16 (5.3) 00 (0.0) 00 (0.0) 00 (0.0) 01 (0.3) 19 (1.1)
Heard that cervical cancer is preventable 51 (17.0) 164 (54.7) 48 (16.0) 19 (6.3) 03 (1.0) 111 (37.0) 396 (22.0)
Preventive measures for cervical cancer
Cervical CA screening 24 (47.1) 99 (60.4) 21 (43.8) 11 (57.9) 01 (33.3) 64 (57.7) 220 (55.6)
HPV vaccination 10 (19.6) 22 (13.4) 11 (22.9) 01 (5.3) 01 (33.3) 25 (22.5) 70 (17.7)
Avoiding risk factors 02 (3.92) 02 (1.2) 00 (0.0) 01 (5.3) 00 (0.0) 18 (16.2) 23 (5.8)

HIV, Human Immunodeficiency Virus; HPV, Human Papilloma Virus